| Line Item | 2022-03-31 | Y/Y |
|---|---|---|
| R&D Expense | $101.8M | +48.4% |
| SG&A Expense | $54.2M | +37.2% |
| Pre-tax Income | -$156.8M | -45.5% |
| Income Tax | -$84K | +76.5% |
| Net Income | -$156.7M | -45.9% |
| EPS (Basic) | -$1.43 | -17.2% |
| EPS (Diluted) | -$1.43 | -17.2% |
| Line Item | 2022-03-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $493.8M | +23.4% |
| Accounts Receivable | $12.2M | +1951.8% |
| Current Assets | $512.9M | +25.4% |
| Total Assets | $515.6M | +25.0% |
| Current Liabilities | $44.5M | +137.2% |
| Total Liabilities | $45.7M | +117.7% |
| Stockholders' Equity | $469.8M | +20.0% |
| Line Item | 2022-03-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$106.1M | -27.3% |
| Capital Expenditures | $254K | +21.0% |
| Investing Cash Flow | -$254K | -21.0% |
| Financing Cash Flow | $200.1M | -47.8% |
| Free Cash Flow | -$106.4M | -27.3% |